This is a single-center, randomized, double-blind, placebo-controlled, sequential, multiple-dose study. The study will be conducted in two parts: Part A (6 cohorts of healthy adults receiving evening dosing) and Part B (one cohort of elderly adults receiving evening dosing).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
24
Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules
E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
Parexel, California Clinical Trials
Culver City, California, United States
Unnamed facility
Glendale, California, United States
Incidence of Adverse events (AEs)
Time frame: 28 days
Plasma concentrations of E2006
Time frame: Part A up to 288 hours postdose; Part B: up to 324 hours postdose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.